Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

iodine I 124-labeled HSP90 inhibitor PUH71

A radioconjugate containing the purine scaffold heat shock protein 90 (Hsp90) inhibitor PUH71 labeled with the radioisotope iodine I 124, with positron emitting activity. Hsp90 inhibitor PUH71 is thought to bind to cytosolic Hsp90 and the endoplasmic reticulum paralogue gp96 (HSP90B1), thereby inhibiting its molecular chaperone function and promoting the degradation of the oncogenic signaling proteins. This induces caspase-dependent apoptosis. The iodine I 124 moiety can be visualized using positron emission tomography (PET) imaging, thereby allowing an assessment of the accumulation of PUH71 in vivo, particularly in tumors. Hsp90, a chaperone protein upregulated in a variety of tumor cells, regulates the folding, stability and degradation of many oncogenic signaling proteins.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:124I-PUH71
Abbreviation:iodine I 124 PUH71
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search